A major diabetes technology company has successfully launched on the stock market, generating significant investor interest on Thursday.
MiniMed, which operates as the diabetes-focused division of medical device corporation Medtronic, announced it successfully completed its initial public stock offering in the United States, bringing in $560 million from investors.
The public offering marks a significant milestone for the diabetes technology sector, as MiniMed transitions from being a subsidiary to operating as an independent publicly-traded entity.
